Early last year, MD+DI predicted that 2022 would be the biggest year yet for diabetes tech – and we weren't wrong. If the latest news and analyst takeaways from the sector's biggest 2023 conference is any indication, however, we haven't seen anything yet.
Marie Thibault, a medtech analyst at BTIG, said overall attendance at the American Diabetes Association (ADA) 83rd Scientific Sessions seemed low compared to pre-COVID and other medical meetings she's attended this year. However, analyst and investor attendance at ADA was particularly high, she noted in a report Monday.
"It is clear diabetes tech remains a high priority for the medtech investment community, in part because of the numerous catalysts and rapidly shifting market dynamics," Thibault wrote. "We remain bullish on the space and expect sales growth rates to keep outpacing most of medtech."
See the following slides for key ADA news and takeaways including the latest data on continuous glucose monitoring (CGM) devices and automated insulin delivery (AID) systems; reimbursement tailwinds; and anticipated product launches in diabetes tech.
